{"filings":[{"id":957316,"accession_number":"0001104659-26-072151","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2026-06-10T13:41:47+00:00","items":["1.02","2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"status":"ready","headline":"Danaher completes $180/share acquisition of Masimo; Masimo becomes wholly owned subsidiary","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Danaher completed acquisition of Masimo at $180.00 per share in cash on June 10, 2026.","Masimo common stock ceased trading on Nasdaq; company will deregister under Section 12(b) of the Exchange Act.","All outstanding Masimo shares cancelled and converted to right to receive $180 cash per share, no interest.","Masimo's credit agreement terminated and paid off; all guarantees released.","Six directors resigned; three executives (Szyman, Meehan, Dadswell) entered separation agreements with 3-month consulting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99921,"accession_number":"0001104659-26-054512","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Masimo shareholders approve Danaher acquisition at $180/share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger adoption proposal passed: 36,981,681 for (99.95% of votes cast), 17,061 against.","Each Masimo share will convert into $180.00 cash; deal expected to close in 2026.","Advisory compensation proposal approved: 34,561,175 for, 1,993,422 against.","Closing remains subject to customary conditions, including regulatory approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99920,"accession_number":"0001104659-26-047839","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Masimo provides supplemental proxy disclosures amid three stockholder lawsuits over Danaher merger","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Three stockholder lawsuits filed in NY and CA allege Masimo's proxy statement is incomplete; company denies merit.","Masimo voluntarily supplements proxy with details on sale process, including Danaher’s final $180/share offer and Party F’s $186/share bid.","Centerview fairness opinion: DCF range $165–$212/share; precedent transaction range $122–$186/share; net debt $372M.","Special meeting remains May 1, 2026; Board continues recommending vote FOR the Danaher merger at $180/share.","Supplemental disclosures do not change merger consideration, timing, or the Board’s recommendation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116218,"accession_number":"0001104659-26-015904","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["1.01","7.01","5.02","9.01"],"status":"ready","headline":"Danaher to acquire Masimo for $180/share cash; total value $9.9B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Masimo shareholders to receive $180.00 per share in cash for each share held.","Total enterprise value of $9.9 billion; transaction unanimously approved by both boards.","Masimo to operate as a standalone business unit within Danaher's Diagnostics segment.","Politan Capital Management, holding significant Masimo shares, agreed to vote in favor.","Closing expected in H2 2026, subject to regulatory approvals and shareholder vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116217,"accession_number":"0000937556-26-000005","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Masimo preliminary Q4 rev $411M (+12% YoY); FY25 rev $1,523M (+9%), non-GAAP EPS >$5.55","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue ~$411M (~12% reported growth; 11% constant currency).","Non-GAAP diluted EPS in Q4 >$1.54, including tariff impact.","Full-year 2025 revenue ~$1,523M (+9% YoY); non-GAAP EPS >$5.55 (high end of guidance).","Noninvasive tech board/instrument shipments: Q4 ~69k, FY ~270k.","CEO reports record incremental contract value from new and expanded hospital agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":1526900000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132667,"accession_number":"0000937556-25-000175","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Masimo targets 7-10% revenue CAGR through 2028; reaffirms FY2025 guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Long-range targets: 7%-10% revenue CAGR through 2028, ~30% operating margin by 2028.","Adjusted EPS target of $8.00 by 2028; cumulative operating cash flow ~$1B from 2026-2028.","Reaffirms FY2025 non-GAAP revenue $1,510-$1,530M, operating profit $412-$424M, EPS $5.40-$5.55.","CEO Katie Szyman emphasized innovation and commercial execution to drive durable growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132666,"accession_number":"0000937556-25-000171","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["1.01","2.03","1.02","9.01"],"status":"ready","headline":"Masimo refinances debt with $250M term loan and $750M revolver maturing 2030","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Paid off prior credit facility (April 2022, Citibank admin) on Dec 1, 2025, and terminated commitments.","New unsecured Credit Facility: $250M term loan + $750M revolver; maturity Dec 1, 2030; option to increase by $400M.","Interest: ABR (spread 0%-0.75%) or Term SOFR (spread 1%-1.75%), based on net leverage; no SOFR credit spread adjustment.","Proceeds used to refinance prior debt and pay fees; future revolver draws for corporate, capex, working capital.","Financial covenants: net leverage ratio and interest charge coverage ratio same as prior agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132665,"accession_number":"0000937556-25-000160","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Masimo Q3 revenue $371.5M (+8.2%), non-GAAP EPS $1.32 (+38%); updates FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP revenue $371.5M (+8.2% YoY); GAAP diluted EPS $0.99; non-GAAP EPS $1.32 (+38% YoY).","Operating margin improved 450 bps YoY; closed Sound United sale to Harman, used proceeds for stock buyback.","Expanded strategic partnership with Philips; announces Investor Day on Dec 3.","FY2025 non-GAAP revenue guidance $1.51-1.53B (+8.5-10% constant currency).","FY2025 non-GAAP EPS guidance $5.40-5.55 including new tariffs; $5.62-5.79 excluding tariffs."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":1114400000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149190,"accession_number":"0000937556-25-000151","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Masimo completes sale of consumer audio business to Harman for ~$328M cash; repays $270M Term Loan","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold Sound United (consumer audio) to Harman on Sept 23, 2025 for net cash ~$328M.","Used proceeds to repay $270M Term Loan plus $1.1M accrued interest.","Pro forma 2024 revenue would be $1.4B vs as-reported $2.1B after divestiture.","Estimated loss on sale of $178.4M recorded in retained earnings in pro forma balance sheet.","Pro forma 2024 net income $27.2M vs as-reported net loss of $304.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149189,"accession_number":"0000937556-25-000138","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Masimo completes sale of consumer audio unit to HARMAN for $350M; to prioritize share repurchases","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed sale of Sound United to Harman (Samsung subsidiary) for $350M cash; received ~$328M at close subject to adjustments.","CEO says sale positions Masimo to focus on core professional healthcare business, accelerate growth, and improve margins.","Masimo plans to prioritize share repurchases with proceeds from the sale.","Centerview Partners, Morgan Stanley, and Sullivan & Cromwell advised Masimo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149188,"accession_number":"0000937556-25-000127","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director William Jellison resigns from Masimo board effective August 18, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Jellison resigned from the Board of Directors effective August 18, 2025.","Resignation was not due to any disagreement with the company on operations, policies, or practices.","Board Chairman Michelle Brennan thanked Jellison for his service during a transformative period.","No replacement has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149187,"accession_number":"0000937556-25-000106","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Masimo Q2 revenue $371M (+8% YoY); Non-GAAP EPS $1.33 (+46%); tariff impact halved","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP revenue $371M (+8% YoY); GAAP diluted EPS $0.82; Non-GAAP diluted EPS $1.33 (+46%).","Non-GAAP revenue $370M (+7% constant currency); core healthcare business driving growth.","Updated FY2025 non-GAAP revenue guidance $1,505-1,535M (8-11% constant currency growth).","Tariff mitigation effective: new guidance including tariffs reduces operating margin to 27.0-27.5% vs 28.3-28.7% ex-tariffs.","CEO highlights expansion of leadership team and tariff mitigation measures reducing impact by 50%."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":742900000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168200,"accession_number":"0000937556-25-000091","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Masimo adds CMO, President Japan/APAC, CHRO; COO Muhsin resigns effective July 1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tim Benner joins as Chief Marketing and Strategy Officer, started June 9, 2025.","Huimin Wang joins as President, Japan & Asia Pacific, started May 13, 2025.","Lisa Hellmann joins as Chief Human Resources Officer, started April 21, 2025.","CFO Micah Young assumes corporate development in addition to finance, IT, IR.","COO Bilal Muhsin resigns effective July 1, 2025; role will not be replaced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168199,"accession_number":"0000937556-25-000086","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Masimo provides cyber incident update; manufacturing at near full capacity, no material revenue impact expected","summary_kind":"llm","event_type":"cyber","confidence":"high","bullets":["Manufacturing running at near full capacity; order-taking, distribution and shipping systems fully operational.","Company expects majority of out-of-pocket remediation costs covered by cyber insurance; costs non-recurring.","Reaffirms updated financial outlook for FY 2025 provided May 6; cyber incident not expected to materially impact revenue.","Incident discovered April 27, 2025; investigation ongoing with third-party experts and law enforcement coordination.","Company continues optimizing systems to process any delayed orders in a timely manner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168194,"accession_number":"0001104659-25-045340","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K/A","filed_at":"2025-05-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Masimo sells consumer audio business (Sound United) to Harman for $350M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale of Viper Holdings (Sound United) to Harman International for base price of $350M cash, subject to working capital adjustments.","Business includes Bowers & Wilkins, Denon, Marantz, Polk, Definitive Technology, Classe, Boston Acoustics brands.","Transaction expected to close after regulatory approvals and customary conditions; Harman is a Samsung subsidiary.","Masimo retains its medical technology and non-audio businesses; proceeds used for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168198,"accession_number":"0001104659-25-045039","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Masimo to sell Sound United consumer audio business to HARMAN for $350M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale to HARMAN, a Samsung subsidiary, for $350M in cash, subject to adjustments.","Divestiture supports Masimo's strategic refocus on core professional healthcare business.","Expected to close by end of 2025, pending regulatory approvals and customary conditions.","Sound United brands include Bowers & Wilkins, Denon, Marantz.","Centerview Partners and Morgan Stanley acted as financial advisors to Masimo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168197,"accession_number":"0001104659-25-045035","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Masimo identifies unauthorized network activity on April 27; manufacturing and shipping operations impacted.","summary_kind":"llm","event_type":"cyber","confidence":"high","bullets":["Discovered unauthorized activity on on-premise network on April 27, 2025; activated incident response and containment protocols.","Certain manufacturing facilities operating at reduced levels; order processing and shipping temporarily disrupted.","Company believes incident not affecting cloud-based systems; investigation ongoing with third-party experts and law enforcement.","Full scope, nature, and impact not yet known; forward-looking statements cite potential legal, reputational, and financial risks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168196,"accession_number":"0000937556-25-000079","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Masimo Q1 non-GAAP EPS $1.36 (+56% YoY); core revenue $372M (+10%); FY guidance cut on tariffs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP revenue $372M, up 10% YoY; non-GAAP EPS $1.36, up 56% from prior year.","Discontinued ops (Sound United) loss of $218M including $295M impairment; held-for-sale.","FY2025 guidance: non-GAAP revenue $1.5B-$1.53B; non-GAAP EPS $4.80-$5.15, includes tariff impact.","Prior FY guidance (ex-tariffs) was EPS $5.30-$5.60; mitigation plans being developed.","CEO Katie Szyman cites strong core healthcare earnings power and double-digit growth."],"consensus_eps_estimate":1.2336,"consensus_eps_actual":-3.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":372000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168195,"accession_number":"0001104659-25-042485","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Masimo shareholders elect directors, ratify auditor, approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected William Jellison, Wendy Lane, Timothy Scannell, Darlene Solomon, Catherine Szyman as directors for 2026 term.","Ratified Grant Thornton LLP as independent auditor for FY2026 (49.1M for, 0.98M against).","Advisory vote to approve named executive officer compensation passed (42.5M for, 5.7M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185399,"accession_number":"0000937556-25-000029","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Masimo Q4 revenue $601M (+9%); Non-GAAP EPS $1.80 (+44%); FY2025 guide sees healthcare growth 8-11%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $601M (+9% YoY); Healthcare $368M (+8%), Non-healthcare $232M (+11%).","GAAP net loss per share ($6.52) due to Sound United impairment; Non-GAAP diluted EPS $1.80 (+44%).","Full-year 2024 healthcare revenue $1,395M (+9%); Non-healthcare revenue $699M (-10%).","FY2025 guidance: Healthcare revenue $1.50B-$1.53B (8-11% constant currency), Non-GAAP EPS $5.10-$5.40.","New CEO Katie Szyman cites strong healthcare momentum and record customer contracts in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":2094400000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185398,"accession_number":"0000937556-25-000022","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["5.02","5.08","8.01","9.01"],"status":"ready","headline":"Masimo amends bylaws; reduces special meeting threshold to 20%, sets April 29 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved Restated Bylaws; stockholders with 20% voting power can call special meetings.","Vote required for stockholder-approved bylaw amendments reduced from 75% to majority of voting power.","Advance notice period for nominations extended to 90-120 days before prior year's proxy mailing.","2025 Annual Meeting scheduled for April 29, 2025; proposals/nominations due March 1, 2025.","Proxy access nominations also due March 1, 2025; universal proxy rules compliance deadline same date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185397,"accession_number":"0000937556-25-000012","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Masimo terminates EVP, General Counsel Tom McClenahan; no replacement named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tom McClenahan terminated as EVP, General Counsel and Corporate Secretary, effective Feb 6, 2025.","No successor or interim replacement announced in the filing.","Company did not disclose the reason for the termination.","McClenahan was a key officer overseeing legal, compliance, and corporate governance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185396,"accession_number":"0000937556-25-000009","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Robert Chapek resigns from Masimo board effective at 2025 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Chapek voluntarily resigned as director, effective at the 2025 annual meeting (date TBD).","Chapek served on board since January 2024 and is a member of Audit Committee.","Resignation not due to any disagreement with company's operations, policies, or practices.","No replacement announced; Chapek will continue in roles until effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185395,"accession_number":"0000937556-25-000007","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Masimo appoints Catherine Szyman as CEO, effective Feb 12; Michelle Brennan becomes Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Katie Szyman appointed CEO effective Feb 12; previously led Edwards Critical Care (acquired by BD); 35+ yrs experience.","Interim CEO Michelle Brennan becomes Chairman; Lead Independent Director Quentin Koffey becomes Vice Chairman.","Szyman compensation: $1M base salary, 100% target bonus, $7M annual LTI target; one-time buyout equity valued at $10M total.","Board continues strategic review of consumer audio and healthcare businesses, with Centerview, Morgan Stanley, Sullivan & Cromwell as advisors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185394,"accession_number":"0000937556-25-000003","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Masimo reports preliminary Q4 2024 revenue ~$601M, healthcare up 9%; issues FY 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 consolidated revenue ~$601M (+9% YoY); healthcare revenue ~$368M (+8% reported, +9% constant currency).","FY 2024 consolidated revenue ~$2,094M (+2%); healthcare $1,395M (+9%); non-healthcare $699M (-10%).","Non-GAAP EPS FY 2024 expected >$4.10 (high end of prior guidance range).","FY 2025 healthcare revenue guidance $1,500M-$1,530M (8-11% constant currency growth); non-GAAP EPS $4.90-$5.10.","Q4 shipments of noninvasive technology boards/instruments ~65K units."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":2094400000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201983,"accession_number":"0000937556-24-000118","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Masimo terminates EVP Business Development Tao Levy as part of healthcare refocus","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Terminated Tao Levy, EVP Business Development, effective November 13, 2024.","Termination part of strategic shift to refocus on core healthcare business.","No replacement named; Levy's departure is involuntary.","Levy was responsible for business development activities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201982,"accession_number":"0000937556-24-000116","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Masimo formalizes interim CEO Michelle Brennan's employment agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary of $1,042,000 per year; eligible for discretionary bonus with target $621,250.","Granted 8,916 RSUs vesting on earlier of March 24, 2025 or appointment of permanent CEO.","Agreement effective Sept 24, 2024 for six-month term; at-will employment.","Brennan continues as Board member; waives board compensation during interim CEO period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201981,"accession_number":"0000937556-24-000106","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Masimo Q3 healthcare revenue up 11.7% CC; raises FY non-GAAP EPS guidance to $3.95-$4.10","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Healthcare revenue $343.3M (+11.7% CC); total revenue $504.6M; 60,500 board/instrument shipments.","GAAP EPS $0.18; Non-GAAP EPS $0.98; GAAP operating income $30.1M, non-GAAP $80.8M.","Raised FY2024 non-GAAP EPS guidance to $3.95-$4.10 from prior $3.80-$4.00; operating income $325-$336M.","Narrowed FY total revenue guidance to $2.075-$2.105B from $2.085-$2.135B; healthcare $1.390-$1.400B.","Interim CEO cites ongoing portfolio review, R&D focus on sizable markets, and strategic review of consumer business."],"consensus_eps_estimate":null,"consensus_eps_actual":0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":1493700000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201980,"accession_number":"0000937556-24-000102","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Masimo terminates CEO Joe Kiani; reaffirms non-GAAP guidance for Q3 and FY 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board terminated CEO Joe Kiani effective Oct 24, 2024 following review by outside counsel.","Michelle Brennan appointed as Interim CEO.","Reaffirms non-GAAP guidance for Q3 2024 and full year 2024, including healthcare segment revenue.","Company continues evaluation of strategic alternatives for its consumer segment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201979,"accession_number":"0000937556-24-000092","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Masimo appoints Timothy Scannell and Wendy Lane to board, expands to eight directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scannell, former Stryker President & COO, brings 30+ years med-tech experience; Lane has 32 years of board service across 16 companies.","Each receives $70K annual cash retainer, a $200K appointment RSU vesting Oct 2025, and annual $200K RSU grants.","Scannell appointed to Compensation Committee; Lane to Nominating, Compliance and Corporate Governance Committee; both to Business Review and Risk Committee.","Board expanded from seven to eight members; both directors are independent under Nasdaq rules.","No family relationships or related-party transactions; standard indemnity agreements entered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218029,"accession_number":"0000937556-24-000085","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["2.02","5.02","5.07","7.01","9.01"],"status":"ready","headline":"Masimo CEO Joe Kiani resigns; Michelle Brennan named interim CEO; board elections tilt to Politan nominees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joe Kiani resigned as CEO on Sept 19, 2024, and filed a California lawsuit claiming 'Good Reason' termination.","Board appointed current director Michelle Brennan as interim CEO effective Sept 24; Korn Ferry hired for CEO search.","Shareholders elected Politan nominees William Jellison and Darlene Solomon to the board; Joe Kiani and Christopher Chavez were not elected.","Reaffirms non-GAAP guidance for Q3 2024 (provided Aug 6); strategic review of consumer businesses continues with Centerview, Morgan Stanley, Sullivan & Cromwell.","Board committed to value-creation initiatives including a potential sale or spin-off of consumer audio and healthcare units."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218028,"accession_number":"0001213900-24-069960","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Masimo updates on consumer business separation; exclusivity expired, exploring multiple deal structures","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusivity with JV partner expired; discussions continue non-exclusively; Masimo may engage other acquirors.","Board evaluating joint venture, spin-off, or sale of consumer audio/health businesses to maximize value.","Masimo to retain professional healthcare and telehealth products; long-term goal of $8 EPS in five years.","Unsolicited inbound requests for consumer audio business received; Morgan Stanley to lead discussions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218027,"accession_number":"0000937556-24-000062","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Masimo Q2 revenue $496.3M, GAAP EPS $0.29, non-GAAP $0.86; raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Healthcare revenue $343.9M, non-healthcare $152.4M; GAAP operating income $28.3M, non-GAAP $72.9M.","GAAP net income $16.0M ($0.29/diluted share); non-GAAP net income $46.6M ($0.86/diluted share).","Raises FY2024 guidance: consolidated revenue $2,085-$2,135M, healthcare $1,385-$1,405M.","FY2024 non-GAAP EPS guidance raised to $3.80-$4.00; Q3 revenue guidance $495-$515M.","CEO cites record-breaking contracting, margin expansion, and innovation for strong results."],"consensus_eps_estimate":null,"consensus_eps_actual":0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":989100000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218026,"accession_number":"0001213900-24-061521","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["5.08","8.01","9.01"],"status":"ready","headline":"Masimo postpones annual meeting to Sept 19, sues Politan over proxy misstatements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting postponed to Sept 19, 2024; new record date Aug 12, 2024.","Filed federal lawsuit against Politan alleging material misstatements and omissions in their proxy materials.","Prior votes and proxies disregarded; all stockholders must resubmit votes after revised proxy statement mailed.","Stockholder proposal and director nomination deadline for the meeting is July 26, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218025,"accession_number":"0000937556-24-000056","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Masimo preliminary Q2 revenue $496M (+9%); healthcare up 22%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue ~$496M, +9% reported, +10% constant currency YoY.","Healthcare revenue ~$344M (+22% reported, +23% constant currency); non-healthcare down 13%.","Incremental value of new healthcare contracts ~$134M, a record Q2.","Driver shipments ~58,000 units; sensor utilization and hospital census improved.","Full Q2 results and FY2024 guidance to be provided on future earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":989100000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218024,"accession_number":"0001213900-24-059677","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Masimo Receives Non-Binding Offer of $850M-$950M for Consumer Business from Potential JV Partner","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Masimo entered non-binding term sheet with Potential JV Partner on May 7, 2024, for sale of majority stake in consumer businesses.","On July 2, 2024, Potential JV Partner provided term sheet confirmation offering $850M-$950M for consumer business on cash/debt free basis.","Exclusivity period extended through mid-August 2024 to allow one to two other companies to conduct due diligence and potentially join.","Masimo intends to negotiate for a higher price as the offer is lower than prior term sheet price.","Board continues to evaluate separation structures including a possible spin-off of consumer business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218023,"accession_number":"0001213900-24-057427","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Masimo COO conditional resignation letter if CEO Kiani removed due to activist Politan","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bilal Muhsin (COO) sent a conditional resignation letter on June 26, 2024, stating he will resign if Joe Kiani is removed as Chairman and CEO.","Muhsin cites 'false accusations' from activist Politan and says he will not stay if Quentin Koffey and Politan take control.","Muhsin's resignation is not due to any disagreement with company operations; it's a protest against potential control change.","The company also disclosed ongoing discussions with a potential JV partner about acquiring a majority of its consumer business (no specifics)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237972,"accession_number":"0001213900-24-054263","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Masimo files investor presentation outlining potential separation of consumer business","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed investor presentation dated June 2024 with estimates and projections for a potential separation of Masimo's consumer business.","Potential separation intended to maximize shareholder value; no transaction has been entered into or completed.","Presentation includes financial estimates for gross margin, R&D, SG&A, and non-GAAP operating margin under separation scenario.","Risks highlighted include failure to obtain regulatory approvals, management distraction, and uncertainty of achieving intended benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237971,"accession_number":"0001213900-24-050527","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Masimo corrects recall scope: 27,600 Rad-G units affected; DOJ investigation ongoing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Recall affects ~7,350 U.S. and ~20,250 non-U.S. Rad-G units due to unintended power state change.","DOJ subpoena and civil investigative demand seek documents on Rad-G/Rad-97 complaints and returns.","Statement at June 5 investor conference corrected to clarify recall unit counts.","Company provides no estimate of resolution or financial impact from DOJ review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237970,"accession_number":"0001213900-24-040915","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Rolf Classon resigns from Masimo board for health reasons; Robert Chapek appointed to Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rolf Classon notified Board on May 3, 2024 of resignation effective May 10, 2024 for personal health reasons.","Resignation not due to any disagreement with Masimo's operations, policies, or practices.","Robert Chapek appointed as member of Audit Committee effective May 8, 2024.","Classon's departure reduces Board size; no other committee changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237969,"accession_number":"0000937556-24-000040","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Masimo Q1 rev $492.8M (healthcare $339.6M), GAAP EPS $0.35, Non-GAAP $0.77; lifts FY2024 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated Q1 revenue $492.8M; healthcare $339.6M, non-healthcare $153.2M.","GAAP net income $18.9M ($0.35 diluted EPS); non-GAAP net income $41.9M ($0.77 diluted EPS).","Sensor manufacturing shift from Mexico to Malaysia improved healthcare gross margins ahead of schedule.","Raises FY2024 healthcare revenue guidance to $1.355-1.385B and non-GAAP EPS to $3.54-3.70.","Pursuing separation of consumer business; management finalizing structure for board review."],"consensus_eps_estimate":null,"consensus_eps_actual":0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":492800000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255446,"accession_number":"0001104659-24-037851","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Masimo board authorizes evaluation of consumer business separation; retains healthcare","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized management to evaluate separation of consumer business (audio + health products: Stork, Freedom).","Masimo will retain professional healthcare and telehealth products; expects improved profitability.","Joe Kiani to remain Chairman and CEO of Masimo and become Chairman of the new company.","Separation timing subject to due diligence, definitive agreements, SEC clearance, and regulatory approvals.","Masimo reaffirms Q1 and fiscal 2024 financial guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255445,"accession_number":"0000937556-24-000015","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Masimo Q4 revenue $548.9M, GAAP EPS $0.63; full-year $2,048.1M; FY2024 guidance $2,045-2,165M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 consolidated revenue $548.9M (healthcare $339.9M, non-healthcare $209.0M).","GAAP EPS $0.63; non-GAAP EPS (updated) $1.25.","Full-year 2023 revenue $2,048.1M; GAAP EPS $1.51; non-GAAP EPS $3.79.","Q1 2024 guidance: revenue $476-501M; full-year 2024 revenue $2,045-2,165M.","CEO cites record contract wins, FDA clearances, and hearables growth as momentum drivers."],"consensus_eps_estimate":null,"consensus_eps_actual":1.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":2048100000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255444,"accession_number":"0000937556-24-000012","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Masimo Director Adam Mikkelson resigns; Craig Reynolds named Audit Chair, Bob Chapek joins committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Adam Mikkelson notified Board of resignation effective Feb 29, 2024, for personal reasons, not due to any disagreement with Masimo.","Mikkelson served as Audit Committee Chair; Craig Reynolds appointed as Audit Committee Chair effective Feb 29, 2024.","Bob Chapek appointed to Compensation Committee and Nominating, Compliance and Corporate Governance Committee, effective immediately.","Mikkelson had served on the Board since October 2016 and chaired Audit, served on Compensation and Nominating committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255443,"accession_number":"0000937556-24-000006","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Masimo appoints former Disney CEO Bob Chapek to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert A. Chapek, former CEO of The Walt Disney Company, appointed Class I director effective January 15, 2024.","Chapek receives $70,000/yr cash compensation plus annual RSU grant of $200,000; appointment RSU of $200,000 vests January 2025.","Appointment supports Masimo's hospital-to-consumer health strategy; Chapek brings media and entertainment expertise.","No family relationships or related party transactions with Masimo directors or officers reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255442,"accession_number":"0000937556-24-000004","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Masimo reports preliminary Q4 2023 rev $541-551M; FY2024 rev guidance $2.045-2.165B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2023 consolidated revenue $541M-$551M; healthcare segment $336M-$341M.","Full-year 2023 consolidated revenue $2.041B-$2.051B; healthcare $1.272B-$1.277B.","FY2024 guidance: consolidated revenue $2.045B-$2.165B; healthcare $1.345B-$1.385B.","FY2024 GAAP EPS $1.91-$2.08; non-GAAP EPS (updated) $3.44-$3.60 (prior $3.00-$3.15).","Non-healthcare revenue expected to decline in FY2024 ($700M-$780M vs ~$771M in 2023)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":2048100000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272907,"accession_number":"0001104659-23-120492","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2023-11-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Delaware court awards Politan $17.8M in fees against Masimo","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Delaware Court of Chancery granted Politan's motion for $17.8 million in attorneys' fees and expenses.","Award relates to Politan's lawsuit against Masimo and certain current and former directors.","Masimo disagrees with the decision but does not intend to appeal due to its discretionary nature."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272906,"accession_number":"0000937556-23-000217","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Masimo appoints Rolf Classon to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rolf A. Classon appointed as a Class II director effective November 3, 2023.","Classon is a former Bayer HealthCare executive with board seats at Fresenius Medical Care, Catalent, and others.","Annual cash compensation of $70,000 plus initial RSU grant valued at $200,000 at next annual meeting.","No family relationships or related-party transactions with Masimo officers/directors.","Classon will help shape next stage of growth, per Chairman and CEO Joe Kiani."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272905,"accession_number":"0000937556-23-000215","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Masimo Q3 rev $478.9M, GAAP EPS $0.20; Q4 guide rev $526-$576M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 consolidated rev $478.9M: healthcare $307.8M, non-healthcare $171.1M.","GAAP net income $10.6M ($0.20 diluted); non-GAAP net income $33.7M ($0.63).","Q4 2023 guidance: rev $526-$576M, healthcare $320-$345M, non-healthcare $206-$231M.","FY 2023 guidance updated: rev $2,025-$2,075M, non-GAAP EPS $2.85-$3.05.","CEO: returning to pre-COVID growth trend; record contracting supports strong 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":1499200000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272904,"accession_number":"0000937556-23-000205","cik":937556,"company_name":"MASIMO CORP","ticker":"MASI","form_type":"8-K","filed_at":"2023-10-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"USITC issues limited exclusion order against Apple Watches for infringing Masimo pulse oximetry patents","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["ITC found Apple violated Section 337; claims 22 & 28 of '502 patent and claims 12, 24, 30 of '648 patent infringed.","Limited exclusion order and cease & desist order issued, effective after 60-day Presidential review period.","Masimo CEO Joe Kiani: 'Even the world's largest company is not above the law.'","Public interest comments from academics, physicians, and Congress supported the exclusion order.","Remedy exempts service/repair and warranty replacements of products purchased before review period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":9361959486.084179,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-10-27T23:59:59+00:00|272904"}